MD3630177T2 - Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax - Google Patents

Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax

Info

Publication number
MD3630177T2
MD3630177T2 MDE20200316T MDE20200316T MD3630177T2 MD 3630177 T2 MD3630177 T2 MD 3630177T2 MD E20200316 T MDE20200316 T MD E20200316T MD E20200316 T MDE20200316 T MD E20200316T MD 3630177 T2 MD3630177 T2 MD 3630177T2
Authority
MD
Moldova
Prior art keywords
treatment
lymphoma
venetoclax
antibody
paradigm
Prior art date
Application number
MDE20200316T
Other languages
English (en)
Inventor
Peter Kelemen
Michael Schwarz
Mark Winderlich
Steffen Heeger
Dominika Weinelt
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MD3630177T2 publication Critical patent/MD3630177T2/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Prezenta divulgare furnizează anticorpi anti-CD19 şi venetoclax pentru utilizare în tratamentul limfomului non-Hodgkin, leucemiei limfocitare cronice şi/sau limfomului limfocitar mic. Anticorpii anti-CD19, în particular MOR00208, şi venetoclaxul sunt administraţi pacienţilor care suferă de limfom non-Hodgkin NHL), leucemie limfocitară cronică (CLL) şi/sau limfom limfocitar mic (SLL) în conformitate cu o paradigmă de tratament specifică pentru a diminua terapia asociată cu sindromul lizării tumorale.
MDE20200316T 2017-05-31 2018-05-30 Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax MD3630177T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173712 2017-05-31
PCT/EP2018/064229 WO2018220040A1 (en) 2017-05-31 2018-05-30 Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment

Publications (1)

Publication Number Publication Date
MD3630177T2 true MD3630177T2 (ro) 2024-01-31

Family

ID=59070416

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20200316T MD3630177T2 (ro) 2017-05-31 2018-05-30 Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax

Country Status (24)

Country Link
EP (2) EP3630177B1 (ro)
JP (2) JP7399713B2 (ro)
KR (2) KR20200010472A (ro)
CN (1) CN110678201A (ro)
AU (1) AU2018276384A1 (ro)
BR (1) BR112019025034A2 (ro)
CA (1) CA3062400A1 (ro)
DK (1) DK3630177T5 (ro)
ES (1) ES2961940T3 (ro)
FI (1) FI3630177T3 (ro)
HR (1) HRP20231229T1 (ro)
HU (1) HUE063119T2 (ro)
IL (2) IL297461B2 (ro)
LT (1) LT3630177T (ro)
MA (1) MA48751B1 (ro)
MD (1) MD3630177T2 (ro)
MX (2) MX2019014330A (ro)
PL (1) PL3630177T3 (ro)
PT (1) PT3630177T (ro)
RS (1) RS64746B1 (ro)
SG (1) SG11201909715VA (ro)
SI (1) SI3630177T1 (ro)
WO (1) WO2018220040A1 (ro)
ZA (1) ZA201907369B (ro)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220241411A1 (en) * 2020-11-30 2022-08-04 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US7109304B2 (en) 2003-07-31 2006-09-19 Immunomedics, Inc. Humanized anti-CD19 antibodies
US8097703B2 (en) 2005-06-20 2012-01-17 Medarex, Inc. CD19 antibodies and their uses
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
PL2059536T3 (pl) 2006-08-14 2014-07-31 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
RU2495882C2 (ru) 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
AP2011005859A0 (en) 2009-02-23 2011-10-31 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to CD19 and their uses.
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR20140071368A (ko) * 2011-08-16 2014-06-11 모르포시스 아게 항ｃｄ19 항체 및 퓨린 유사체를 이용한 병용 요법
BR112013033919B1 (pt) 2011-08-16 2022-11-16 Morphosys Ag Uso de um anticorpo específico para cd19
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
MX2019004942A (es) * 2016-10-28 2019-08-12 Morphosys Ag Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.

Also Published As

Publication number Publication date
JP2024028865A (ja) 2024-03-05
RU2019139552A (ru) 2021-07-01
KR20240117655A (ko) 2024-08-01
HRP20231229T1 (hr) 2024-02-02
EP3630177A1 (en) 2020-04-08
PL3630177T3 (pl) 2024-04-08
BR112019025034A2 (pt) 2020-06-30
DK3630177T3 (da) 2023-10-16
CA3062400A1 (en) 2018-12-06
LT3630177T (lt) 2023-10-25
ZA201907369B (en) 2024-04-24
IL297461A (en) 2022-12-01
RU2019139552A3 (ro) 2021-09-22
SG11201909715VA (en) 2019-11-28
KR20200010472A (ko) 2020-01-30
IL270855A (en) 2020-01-30
IL270855B2 (en) 2023-03-01
CN110678201A (zh) 2020-01-10
RS64746B1 (sr) 2023-11-30
WO2018220040A1 (en) 2018-12-06
JP7399713B2 (ja) 2023-12-18
IL297461B2 (en) 2024-09-01
HUE063119T2 (hu) 2024-01-28
EP3630177B1 (en) 2023-08-09
AU2018276384A1 (en) 2019-11-07
MX2019014330A (es) 2020-02-05
EP4268900A2 (en) 2023-11-01
MX2023013228A (es) 2024-04-16
ES2961940T3 (es) 2024-03-14
DK3630177T5 (da) 2024-09-02
PT3630177T (pt) 2023-11-10
EP4268900A3 (en) 2024-03-06
MA48751B1 (fr) 2023-11-30
FI3630177T3 (fi) 2023-10-18
IL297461B1 (en) 2024-05-01
JP2020521777A (ja) 2020-07-27
MA48751A (fr) 2020-04-08
SI3630177T1 (sl) 2023-12-29
IL270855B (en) 2022-11-01

Similar Documents

Publication Publication Date Title
BR112016025437A2 (pt) combinação de lenalidomida e construto de polipeptídeo, e usos destes
MX2024000151A (es) Composiciones y usos de las mismas para el tratamiento de afecciones malignas de celulas t usando terapias de celulas adoptivas.
PH12020552229A1 (en) Il-11ra antibodies
MD3313441T2 (ro) Modularea imună și tratament al tumorilor solide cu anticorpi care leagă specific CD38
RS54456B1 (en) TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
PH12021550553A1 (en) Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
PH12019500643A1 (en) Antibodies that bind interleukin-2 and uses thereof
WO2015110923A3 (en) Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia
MX2021005761A (es) Anticuerpos anti-proteína alfa reguladora de señal (anti-sirpalfa) humanizados.
WO2016191675A3 (en) Antibodies against glypican-3 and their uses in cancer diagnosis and treatment
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
EA202191170A1 (ru) Комбинированная терапия для лечения гематологических заболеваний
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
MX2021006244A (es) Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
MD3630177T2 (ro) Paradigmă de tratament pentru un tratament combinat cu anticorpi anti-CD19 și venetoclax
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
MX2018002241A (es) Combinaciones y sus usos.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2021010313A (es) Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.